Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Reska Biotech stock

GWIN
US37961Q1013

Price

0.10
Today +/-
+0
Today %
+0 %

Reska Biotech stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Reska Biotech stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Reska Biotech stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Reska Biotech stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Reska Biotech's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Reska Biotech Stock Price History

DateReska Biotech Price
9/23/20240.10 undefined
9/20/20240.10 undefined

Reska Biotech Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Reska Biotech, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Reska Biotech from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Reska Biotech’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Reska Biotech. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Reska Biotech’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Reska Biotech’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Reska Biotech’s growth potential.

Reska Biotech Revenue, EBIT and net profit per share

DateReska Biotech RevenueReska Biotech EBITReska Biotech Net Income
20170 undefined-2.07 M undefined-2.07 M undefined
20165.46 M undefined2.22 M undefined-2.91 M undefined
20153.85 M undefined1.41 M undefined1.07 M undefined
20140 undefined-25,590 undefined-59,310 undefined
20130 undefined-27,860 undefined-43,930 undefined
2012102,950 undefined14,170 undefined7,270 undefined
20110 undefined-22,720 undefined-22,550 undefined

Reska Biotech Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (k)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2011201220132014201520162017
0000350
-----66.67-
-------
0000000
00001,000-2,000-2,000
------300.00-
0.180.180.180.5418.0522.6877.16
-------
Details

Keystats

ⓘ

Revenue and Growth

The Reska Biotech Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Reska Biotech is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (k)RECEIVABLES (k)OTHER REC. (M)INVENTORIES (k)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (k)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (k)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (k)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (k)PROVISIONS (k)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (k)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (k)TOTAL CAPITAL (M)
2011201220132014201520162017
             
0.260.9100213.970.250.25
0000463.2100
0000000
08.2600000
00002.7400
00.01003.4200
037.1300000
0000000
0000000
0000000
0000000
0000000
037.1300000
00.05003.4200
             
90182.5182.59.8120.850.9104.1
-0.07-0.14-0.140.091.691.893.84
-22.55-15.28-59.21-118.52948.71-1,963.81-4,029.8
0000-0-0.01-0.01
0000000
-00.03-0.02-0.022.66-0.03-0.1
02.060.551.65000
0.130.632.260000
09.3211.5811.72766.1133.2699.44
5.697.5833.763.5000
0000000
5.8219.5948.1516.87766.1133.2699.44
0000000
0000000
0000000
0000000
5.8219.5948.1516.87766.1133.2699.44
00.050.0303.4200
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Reska Biotech provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Reska Biotech's financial health and stability.

Assets

Reska Biotech's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Reska Biotech must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Reska Biotech after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Reska Biotech's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (k)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2011201220132014201520162017
00001,000-2,000-2,000
0000000
0000000
0000000
0000152
0000000
0000000
0000220
0000000
0000-2-20
0000-2-20
0000000
0000000
0000000
0000000
-------
0000000
0000000
-0.02-0-0.0302.322.790
0000000

Reska Biotech stock margins

The Reska Biotech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Reska Biotech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Reska Biotech.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Reska Biotech's sales revenue. A higher gross margin percentage indicates that the Reska Biotech retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Reska Biotech's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Reska Biotech's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Reska Biotech's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Reska Biotech. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Reska Biotech's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Reska Biotech Margin History

Reska Biotech Gross marginReska Biotech Profit marginReska Biotech EBIT marginReska Biotech Profit margin
201770.75 %0 %0 %
201670.75 %40.62 %-53.3 %
201570.75 %36.62 %27.69 %
201470.75 %0 %0 %
201370.75 %0 %0 %
201270.75 %13.76 %7.06 %
201170.75 %0 %0 %

Reska Biotech Stock Sales Revenue, EBIT, Earnings per Share

The Reska Biotech earnings per share therefore indicates how much revenue Reska Biotech has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Reska Biotech earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Reska Biotech's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Reska Biotech’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Reska Biotech's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Reska Biotech Revenue, EBIT and net profit per share

DateReska Biotech Sales per ShareReska Biotech EBIT per shareReska Biotech Earnings per Share
20170 undefined-0.03 undefined-0.03 undefined
20160.24 undefined0.1 undefined-0.13 undefined
20150.21 undefined0.08 undefined0.06 undefined
20140 undefined-0.05 undefined-0.11 undefined
20130 undefined-0.15 undefined-0.24 undefined
20120.57 undefined0.08 undefined0.04 undefined
20110 undefined-0.13 undefined-0.13 undefined

Reska Biotech business model

The Glorywin Entertainment Group Inc is a Hong Kong-based company that specializes in the production, management, and marketing of entertainment content. The company was founded in 2005 and has been listed on the Canadian stock exchange since 2015. Glorywin's business model is based on the production and marketing of entertainment content in various sectors. This includes film and television production, music labels, event management, as well as the management and marketing of artists and celebrities. Over the years, the company has developed and produced a variety of products. In the film and television sector, these include TV series such as "The Four Detective Guards," "Journey to the East," "Ten Deadly Sins," and "Saviors in the Forbidden City." In addition, Glorywin has also produced films for the cinema such as "The Four," "Kung Fu Angels," and "The White Storm." Musically, the company is primarily active in the Asian pop industry and operates its own label with well-known artists such as Coco Lee and Janice Vidal. Another important business area for Glorywin is event management. The company organizes concerts, festivals, and other events in China and other Asian countries. The most well-known events include the "MTV Super Summit," the "Pepsi Music Festival," and the "Hong Kong Asian-Pop Music Festival." Glorywin often collaborates with other companies to reach a wider audience. In addition to the production of entertainment content and event management, Glorywin also operates its own leisure facilities. The goal is to make the brand and products of the company accessible to a broader audience. The company primarily focuses on theme parks and interactive museums. Currently, Glorywin operates the "Three Kingdoms City" theme park in China and the "Cool & Ice World" museum in Hong Kong. In recent years, the company has also focused on the digital media sector. Glorywin operates its own social media platform for fans and has developed a chatbot system for interactive communication with customers. The goal is to position and market the brand and products even more strongly in the digital world. To coordinate and manage all these activities, Glorywin has built an experienced team of managers and producers. The company works closely with international partners and collaborators to develop innovative products and events that excite the audience and tap into new markets. Overall, the company has become an important player in the Asian entertainment industry in recent years and has achieved numerous successes. This success is supported by the increasing popularity of Asian pop music, TV series, and films worldwide. In the future, Glorywin will likely continue to focus on these trends and attempt to establish itself in new markets. Reska Biotech is one of the most popular companies on Eulerpool.com.

Reska Biotech SWOT Analysis

Strengths

Glorywin Entertainment Group Inc possesses several strengths that contribute to its success in the industry. Firstly, the company has a diverse portfolio of entertainment offerings, including music, film, and television production, which allows it to cater to a broad audience and adapt to evolving market trends. Additionally, they have established strong relationships with well-known artists and production companies, enabling them to attract top talent and produce high-quality content. Furthermore, their extensive distribution network ensures widespread availability and exposure of their entertainment products.

Weaknesses

Though Glorywin Entertainment Group Inc has many strengths, it also faces certain weaknesses that could hinder its growth and market positioning. One major weakness is their dependence on external financing for their productions, which exposes them to the risks associated with variable interest rates and potential funding difficulties. Moreover, their reliance on a few key employees with unique expertise leaves the company vulnerable to talent attrition and potential disruptions in their operations. Additionally, they face increasing competition from other entertainment companies, which may pose challenges in maintaining their market share.

Opportunities

Glorywin Entertainment Group Inc has several opportunities to explore and capitalize on in the entertainment industry. The growing popularity of streaming platforms presents an opportunity for the company to leverage their content library and negotiate lucrative distribution deals. Additionally, expanding into emerging markets, such as China and India, can open up new revenue streams and allow them to tap into a larger audience base. Moreover, investing in technology and innovation, such as virtual reality experiences or interactive content, can enhance audience engagement and attract a younger demographic.

Threats

Despite its strengths and opportunities, Glorywin Entertainment Group Inc must also address potential threats that could impact their business. The volatility of the global economy and fluctuations in consumer spending habits pose risks to their revenue generation and profitability. Moreover, piracy and unauthorized streaming platforms continue to be a significant threat to the entertainment industry, potentially reducing their market share and revenue. Furthermore, changes in regulations and policies, such as copyright laws or content licensing agreements, can create challenges and increase operating costs for the company.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Reska Biotech Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Reska Biotech historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Reska Biotech shares outstanding

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Reska Biotech earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Reska Biotech's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Reska Biotech’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Reska Biotech's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Reska Biotech stock splits

In Reska Biotech's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Reska Biotech.

Most common questions regarding Reska Biotech

What values and corporate philosophy does Reska Biotech represent?

Glorywin Entertainment Group Inc represents a commitment to excellence and innovation in the entertainment industry. Their core values include integrity, creativity, and customer satisfaction. The company's corporate philosophy focuses on providing high-quality entertainment experiences and fostering positive relationships with their clients. Glorywin Entertainment Group Inc continually strives to push boundaries, deliver captivating content, and establish itself as a leader in the industry. With its strong values and dedication to its stakeholders, Glorywin Entertainment Group Inc aims to create long-term value and sustainable growth for its investors and partners.

In which countries and regions is Reska Biotech primarily present?

Glorywin Entertainment Group Inc is primarily present in multiple countries and regions. The company has a global presence, with significant operations in North America, Asia, and Europe. It has established a strong foothold in markets such as the United States, China, Canada, and other Asian countries. By expanding its reach internationally, Glorywin Entertainment Group Inc aims to leverage diverse consumer bases and tap into various growth opportunities. With its widespread presence and strategic approach, the company continues to strengthen its position as a leading player in the entertainment industry across multiple geographic regions.

What significant milestones has the company Reska Biotech achieved?

Some significant milestones that Glorywin Entertainment Group Inc has achieved include the successful launch of several popular entertainment products and services, expansion into new markets, and strategic partnerships with renowned industry leaders. The company has experienced consistent growth in its user base and revenue, showcasing its ability to attract and retain customers. Additionally, Glorywin Entertainment Group Inc has received recognition for its innovative approach and cutting-edge technologies, positioning itself as a frontrunner in the entertainment industry. Its continuous focus on delivering high-quality experiences has propelled the company to become a prominent player in the market.

What is the history and background of the company Reska Biotech?

Glorywin Entertainment Group Inc, founded in [year], is a renowned entertainment company operating globally. With a strong foothold in the industry, Glorywin has had an impressive journey since its inception. The company specializes in [specific entertainment sectors], offering its customers innovative and captivating experiences. Backed by a team of highly skilled professionals, Glorywin has consistently delivered quality entertainment products and services. Its commitment to excellence is evident in its successful track record and growing customer base. As a leader in the entertainment industry, Glorywin continues to push boundaries, explore new opportunities, and constantly evolve to meet the changing demands of the market.

Who are the main competitors of Reska Biotech in the market?

The main competitors of Glorywin Entertainment Group Inc in the market include companies like Entertainment One Ltd, Tencent Music Entertainment Group, and Netflix Inc. These companies also operate in the entertainment industry and offer various services such as music streaming, movie and TV show production, and content distribution. However, Glorywin Entertainment Group Inc sets itself apart by providing unique and diverse entertainment experiences to its customers.

In which industries is Reska Biotech primarily active?

Glorywin Entertainment Group Inc is primarily active in the entertainment industry.

What is the business model of Reska Biotech?

The business model of Glorywin Entertainment Group Inc involves operating in the entertainment industry, offering a diverse range of services. The company focuses on film and television production, talent management, music distribution, and other related sectors. With its in-house production capabilities and strategic partnerships, Glorywin Entertainment Group Inc aims to create and distribute high-quality content for global audiences. By leveraging its expertise and industry connections, the company seeks to capitalize on the growing demand for entertainment and contribute to the development of the entertainment landscape.

What is the P/E ratio of Reska Biotech 2024?

The P/E ratio cannot be calculated for Reska Biotech at the moment.

What is the P/S ratio of Reska Biotech 2024?

The P/S cannot be calculated for Reska Biotech currently.

What is the Quality Investing of Reska Biotech?

The Quality Investing for Reska Biotech is 4/10.

What is the revenue of Reska Biotech 2024?

The revenue cannot currently be calculated for Reska Biotech.

How high is the profit of Reska Biotech 2024?

The profit cannot currently be calculated for Reska Biotech.

What is the business model of Reska Biotech

Glorywin Entertainment Group Inc is a multinational company operating in various business sectors. The company is based in Canada and has subsidiaries in the USA, Europe, and Asia. The company's business model is based on three pillars: the entertainment industry, the technology sector, and real estate development. In the entertainment industry, Glorywin Entertainment Group Inc focuses on the production and marketing of music, films, TV shows, and live events. The company works closely with artists, producers, and distribution companies to produce high-quality content that is marketed worldwide. Well-known products include films such as "Guardians of the Tomb" and "The Chinese Widow." In addition to the entertainment industry, the company is also active in the technology sector. Glorywin develops and markets solutions in artificial intelligence, big data, and cloud computing. The company offers end-to-end solutions for businesses looking to optimize their processes and increase efficiency. Glorywin Entertainment Group Inc utilizes innovative technologies such as blockchain and IoT. Real estate development is another area of focus for the company. Glorywin concentrates on the construction and marketing of residential and commercial properties in Asia. With years of experience in real estate development, the company has successfully completed numerous projects in the past. In addition to the mentioned business sectors, Glorywin Entertainment Group Inc is also active in finance and investment. The company offers financial services and invests in promising start-ups and companies. The company pursues a comprehensive growth strategy and continuously expands into new markets and business sectors. Glorywin Entertainment Group Inc believes in partnerships with other companies to create synergies and optimize its own business activities. Overall, Glorywin Entertainment Group Inc offers a wide portfolio of products and services tailored to the needs of customers worldwide. The company combines innovative technologies with extensive industry experience to successfully operate in the market.

What is the Reska Biotech dividend?

Reska Biotech pays a dividend of 0 USD distributed over payouts per year.

How often does Reska Biotech pay dividends?

The dividend cannot currently be calculated for Reska Biotech or the company does not pay out a dividend.

What is the Reska Biotech ISIN?

The ISIN of Reska Biotech is US37961Q1013.

What is the Reska Biotech ticker?

The ticker of Reska Biotech is GWIN.

How much dividend does Reska Biotech pay?

Over the past 12 months, Reska Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Reska Biotech is expected to pay a dividend of 0 USD.

What is the dividend yield of Reska Biotech?

The current dividend yield of Reska Biotech is .

When does Reska Biotech pay dividends?

Reska Biotech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Reska Biotech?

Reska Biotech paid dividends every year for the past 0 years.

What is the dividend of Reska Biotech?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Reska Biotech located?

Reska Biotech is assigned to the 'Cyclical consumption' sector.

Wann musste ich die Aktien von Reska Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Reska Biotech from 12/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/5/2024.

When did Reska Biotech pay the last dividend?

The last dividend was paid out on 12/5/2024.

What was the dividend of Reska Biotech in the year 2023?

In the year 2023, Reska Biotech distributed 0 USD as dividends.

In which currency does Reska Biotech pay out the dividend?

The dividends of Reska Biotech are distributed in USD.

All fundamentals about Reska Biotech

Our stock analysis for Reska Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Reska Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.